Previous 10 | Next 10 |
2023-07-24 18:21:28 ET Summary Bristol-Myers Squibb Company made a $35 million equity investment into Immatics N.V. The partnership with Bristol-Myers Squibb brought $15 million opt-in payment; Immatics also is eligible to earn up to $490 million in milestone payments in addition ...
2023-07-24 10:00:53 ET Summary Immatics recently posted updated data and went up a lot. IMTX stock is up hugely in the last 4 months. The company is developing solid tumor biologics and has a decent cash runway. Immatics ( IMTX ) is up 66% since I covered it ...
2023-07-24 07:34:11 ET A clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, Immatics ( NASDAQ: IMTX ) stock price surged 8.3% on Monday as the company said that Bristol Myers Squibb ( NYSE: BMY ...
Tuebingen , Germany and Houston , TX , Ju ly 24 , 202 3 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunother...
2023-05-16 07:19:45 ET Immatics press release ( NASDAQ: IMTX ): Q1 GAAP EPS of -€0.26. Revenue of €9.79M (-90.5% Y/Y). For further details see: Immatics GAAP EPS of -€0.26, revenue of €9.79M
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 67% confirmed ORR in an interim clinical update on heavily pre-treated 11 patients in Phase 1b dose expansion Cohort A with median duration of response not reached at a median follow-up time of 8.5 months at data cut-off Objective ...
2023-05-02 08:15:43 ET German biotech Immatics N.V. ( NASDAQ: IMTX ) added ~30% in the pre-market Tuesday after announcing interim data from an ongoing Phase 1b trial for its IMA203 TCR-T monotherapy in heavily pre-treated patients with solid tumors as a last-line option. Ac...
Company to host conference call today, May 2, at 8:30 am EDT / 2:30 pm CEST Update covers data from 11 heavily pre-treated, last-line patients in Phase 1b dose expansion Cohort A treated with IMA203 TCR-T monotherapy against PRAME Objective response rate (ORR): 6...
Bristol Myers Squibb exercised its first option and entered into a global license agreement with Immatics for the most advanced TCR-T product candidate from the companies’ ongoing collaboration to develop four TCR-based adoptive cell therapies targeting solid tumors Immatics to receive...
2023-03-31 13:44:40 ET Mizuho Securities has launched its coverage of Immatics N.V. ( NASDAQ: IMTX ), citing an underappreciated opportunity in the German biotech in the race to develop T-cell receptor (TCR)-based immune-oncology therapies. The decision comes as Immatics (...
News, Short Squeeze, Breakout and More Instantly...
Houston, Texas and Tuebingen, Germany, July 18, 2024 – Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the first proof-of-conc...
2024-07-12 10:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-12 13:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...